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Abstract
Background: Deliberate self-poisoning with older pesticides such as organophosphorus compounds are commonly fatal
and a serious public health problem in the developing world. The clinical consequences of self-poisoning with newer
pesticides are not well described. Such information may help to improve clinical management and inform pesticide
regulators of their relative toxicity. This study reports the clinical outcomes and toxicokinetics of the neonicotinoid
insecticide imidacloprid following acute self-poisoning in humans.
Methodology/Principal Findings: Demographic and clinical data were prospectively recorded in patients with imidacloprid
exposure in three hospitals in Sri Lanka. Blood samples were collected when possible for quantification of imidacloprid
concentration. There were 68 patients (61 self-ingestions and 7 dermal exposures) with exposure to imidacloprid. Of the
self-poisoning patients, the median time to presentation was 4 hours (IQR 2.3–6.0) and median amount ingested was 15 mL
(IQR 10–50 mL). Most patients only developed mild symptoms such as nausea, vomiting, headache and diarrhoea. One
patient developed respiratory failure needing mechanical ventilation while another was admitted to intensive care due to
prolonged sedation. There were no deaths. Median admission imidacloprid concentration was 10.58 ng/L; IQR: 3.84–
15.58 ng/L, Range: 0.02–51.25 ng/L. Changes in the concentration of imidacloprid in serial blood samples were consistent
with prolonged absorption and/or saturable elimination.
Conclusions: Imidacloprid generally demonstrates low human lethality even in large ingestions. Respiratory failure and
reduced level of consciousness were the most serious complications, but these were uncommon. Substitution of
imidacloprid for organophosphorus compounds in areas where the incidence of self-poisoning is high may help reduce
deaths from self-poisoning.
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Introduction
Intentional self-poisoning with pesticides is an important public
health problem in the Asia- Pacific region with an estimated
300,000 deaths occurring each year [1,2]. A large number of these
deaths are due to poisoning with organophosphorus insecticides
which are an integral part of agriculture within this region [2].
Due to the intrinsic toxicity of these compounds, new pesticides
continue to be developed and released to the market which almost
always occurs in the absence of data on direct human toxicity.
Instead, human toxicity is often extrapolated from toxicological
studies in animals, the relevance of which is poorly defined.
Therefore, data reporting the outcomes from human exposures to
these newer insecticides are required. This information can assist
in the risk assessment and clinical management of patients with
acute exposures and support policy decisions by regulatory
agencies. Previous restrictions in the availability of highly toxic
compounds appeared to substantially reduce deaths from
poisoning [3,4,5] without harming agricultural outputs [5].
The neonicotinoids are a new major class of highly potent
insecticides that are used for crop protection and flea control [6].
Insecticides within this class include imidacloprid, acetamiprid,
clothianidine, and thiocloprid. These insecticides are agonists at
the nicotinic acetylcholine receptors (nAChRs), particularly the
a4b2 subtype [7,8], which induces neuromuscular paralysis and
eventually death. They are highly selective for nAChRs in insects
compared with mammals, which should reduce morbidity and
mortality in cases of human poisoning [7]. If clinical data on
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5127human exposures support this, they may potentially replace the
more widely used cholinesterase inhibitors (organophosphorus and
carbamate compounds) in crop protection.
Imidacloprid (CAS 138261-41-3; figure 1) is the most
commonly used neonicotinoid insecticide in Sri Lanka. On the
basis of animal studies it is classified as moderately hazardous
(Class II WHO; toxicity category II EPA) [9,10]. It has low acute
lethal toxicity to mammals, birds, and fish: the acute oral LD50
(dose that is lethal in 50% of animals) of imidacloprid in rats is
475 mg/kg and the acute dermal LD50 exceeds 5000 mg/kg. It
also does not cause eye irritation (rabbits) or skin sensitization
(guinea pigs) [11].
Data on human exposure to imidacloprid is limited to
occupational exposures [12,13,14,15] and 13 case reports of self-
poisoning [14,16,17,18,19,20,21]. Mild clinical effects such as
tachycardia, hypertension, mydriasis, nausea and vomiting occur,
but more serious sequelae including respiratory failure, seizures
[15,17,20] and even death [16,18,21] are reported. This raises
serious doubts about its assumed superior safety profile over older
insecticides. However, in the majority of cases the concentration of
imidacloprid was not quantified so it was not possible to confirm
exposure or consider dose in the risk assessment.
In this study we sought to further describe the spectrum of
toxicity and clinical outcomes relative to the admission plasma
concentration in patients with acute imidacloprid poisoning.
Methods
Ethics statement
This observational study was approved by Human Research
Ethics committees of the University of Colombo Faculty of
Medicine, The Sri Lankan Medical Association, The Australian
National University and Oxfordshire, UK. Ethics approval
includes provision of a single blood sample on admission, regular
clinical reviews during hospitalisation and publication of de-
indentified clinical data. Multiple blood samples were obtained as
part of a smaller sub-study which required additional written
consent. In all cases, informed verbal consent was obtained from
the patient or a relative in their native language.
Set up
A prospective observational cohort study of all poisoning
presentations was established during 2002 in three hospitals in
the North Central and North Western provinces of Sri Lanka and
the cohort was extended to Central province during the year 2005.
Inclusion and exclusion criteria
All patients presenting to a study hospital with a history of
imidacloprid exposure were considered for this study. Patients
under 14 years, pregnant women and patients presenting with co-
ingestions are excluded from the study.
Data collection procedure
Clinical observations of all patients with imidacloprid poisoning
were prospectively recorded on a specially designed data base from
March 2002 to March 2007. The poison ingested was identified
from the patient’s or relative’s history, examination of the bottle
label and/or the doctor’s comments on transfer letters. Blood tests
such as full blood count, biochemistry or cholinesterase activity
were not performed prospectively as there is limited availability of
such services in these predominantly rural hospitals.
Blood samples were collected from patients for quantification of
the concentration of imidacloprid and other biochemical assays at
a later date. Following collection, the plasma was promptly
separated and samples were stored at 223uC and transported to
the University of Queensland, Australia on dry ice for analysis.
Samples were analyzed by HPLC (Shimadzu) with MSMS
detection (Applied Biosystems API2000) of imidacloprid (MRM
255.9/208.9) and internal standard d4-Imidacloprid (MRM
260.0/213.1) at 3.7 min. Separation of the imidacloprid peak
was performed using Strata C18 (5 mm62 mm) online solid phase
extraction and Gemini (50 mm62 mm) analytical columns
(Phenomenex) using a standard valve configuration [22], the
3 minute equilibration step and 6 minute gradient shown in
table 1. Solvent A (Pumps A & B) and Solvent B (Pump C)
contained 0.1% formic acid with acetonitrile, water and methanol
in the ratios 5:95:0 and 90:5:5, respectively. Samples were
prepared by combining plasma (10 mL), d4-imidacloprid (2 mg/
mL) in zinc (II) sulfate solution (100 mM, 20 mL) and acetonitrile
(50 mL). Each sample was prepared by combining the three
components, vortex mixing (5 sec), centrifugation (5 min at
4000 rpm), transfer of supernatant (,70 mL) and LCMS injection
of 50 mL (Table 1).
Biochemical analyses were conducted by Queensland Health
Forensic and Scientific Services at Princess Alexandra Hospital,
Australia. This service is accredited by the National Association of
Testing Authorities, Australia and certified to International
Standards (ISO 9001).
Figure 1. Chemical structure of imidacloprid.
doi:10.1371/journal.pone.0005127.g001
Table 1. LC Events
LC Events
Time (min) device parameter value
23 Valve Switch A
23–0 Pumps Flow (mL/min) 0.8
%A:%B:%C 50:50:0
0–1.45 Pumps Flow (mL/min) 0.2
%A:%B:%C 100:0:0
1.50 Valve Switch B
1.50 %A:%B:%C 0:100:0
1.50–6.00 Pumps Flow (mL/min) 0.6
4.00 Pumps %A:%B:%C 0:0:100
4.50 Pumps %A:%B:%C 0:100:0
6.00 Controller stop
doi:10.1371/journal.pone.0005127.t001
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statistical Program STATA IC 10.
Results
Over the 5 year period, 68 patients presented to study hospitals
with a history of imidacloprid exposure. Seven cases were
occupational dermal exposures, all of whom remained asymptom-
atic and were discharged within 24 hours of admission. Five
patients reported co-ingestion with another pesticide and were
excluded from further analysis, leaving 56 patients with acute
imidacloprid self-poisoning.
The median time to present to a study hospital since ingestion
was 4 hours (IQR 2.3–6.0 hours). The median volume reported as
ingested in self-poisoning was 15 mL (IQR: 10–50); although in 23
the volume ingested was unknown.
The majority of patients (54/56) had only mild symptoms such
as nausea, vomiting, headache, dizziness, abdominal pain, and
diarrhoea during the hospital stay which was largely self-resolving.
The median Glasgow Coma Score (GCS) on presentation was 15
(IQR: 10–15). There were no deaths giving a case fatality of 0%
(95% CI: 0.0–5.2%). However, two patients developed more
severe symptoms requiring management in an intensive care unit
and are described in more detail below.
Case 1
A 35 year old woman was admitted to a peripheral hospital soon
after ingestion of an unknown amount of imidacloprid. Due to an
initial lack of history, she had been managed as a case of
organophosphorus pesticide poisoning. She received forced
emesis, 1.2 mg of atropine and 1g of pralidoxime before her
transfer to the study hospital. At this time, 2 hours post ingestion,
she was agitated and had a blood pressure of 110/70 mmHg,
regular pulse rate of 120/minute, pupil diameter 3 mm bilaterally
and clear lungs. She received a bolus dose of haloperidol (5 mg
intramuscularly) for agitation. At 16 hours after ingestion she
developed a respiratory arrest requiring endotracheal intubation
using atracurium 25 mg and midazolam 5 mg. She received an
atropine infusion at 1.2 mg/hour and prophylactic cefuroxime
750 mg 8 hourly and metronidazole 500 mg every 8 hours for
suspected pulmonary aspiration. On her second day in ICU, she
became hypotensive which was treated with dopamine infusion.
Other treatments included regular pralidoxime (1g every 6 hours)
and chest physiotherapy. She was extubated on her 4
th ICU day
after 3 days of mechanical ventilation and discharged home 9 days
post-ingestion with no apparent residual effects. During her
recovery the patient reported a history of imidacloprid only. This
was subsequently confirmed on laboratory testing of a blood
sample obtained 5 hours post-ingestion when the plasma concen-
tration of imidacloprid was 44.6 ng/L (Figure 2) and the butyryl
cholinesterase activity was normal.
Case 2
A 26 year old man presented to a peripheral hospital following
ingestion of an unknown amount of imidacloprid under the
influence of alcohol. He received forced emesis and atropine (3 mg
bolus followed by infusion of 2 mg/hour) and was then transferred
to one of the study hospitals. On admission to the study hospital
(4.5 hours post-ingestion) he had vomiting, a regular pulse rate of
84/minute, blood pressure 100/80 mmHg, pupil diameter 6 mm
bilaterally, respiratory rate 40/minute, pulse oximetry was 100%
and GCS 3/15. The patient was transferred to the ICU 9 hours
post-ingestion for closer monitoring. He received nebulised
salbutamol and intravenous cefuroxime and metronidazole for
prophylaxis against aspiration pneumonia. His clinical condition
improved within 24 hours and he was discharged alive 3 days
later. Blood samples were not available to confirm exposure in this
patient.
Toxicokinetics and biochemistry
Of the 56 patients with imidacloprid self-poisoning, 13 patients
provided serial blood samples, 38 patients provided a single blood
sample, and 5 patients refused to give any samples. Blood samples
from the first 33 cases were analysed as described and the results of
imidacloprid quantification are shown in figure 2. Exposure was
confirmed in 28 patients, with a median admission plasma
concentration of 10.58 ng/L; IQR: 3.84–15.58 ng/L and range:
0.02–51.25 ng/L. In 5 patients the concentration was less than the
level of quantification (0.008 ng/L), consistent with minimal
exposure to imidacloprid.
Imidacloprid was only detected in eight of the patients who
provided serial blood samples but in one patient the plasma
concentrations were all less than 0.3 ng/L. The concentration-
time profiles for these seven patients are shown in Figure 3 and
demonstrate a rapid initial absorption with high concentrations
being noted on admission. However, the concentration remained
elevated for up to 10–15 hours post-ingestion, which might suggest
that absorption and/or elimination are saturable (zero-order) or
prolonged at high doses. In one of the patients there was a rapid
decrease in concentration soon after the admission sample which
might represent a distribution phase; the reason for this sample
differing from the others is not apparent from this data.
Quantification of metabolite production may further define the
toxicokinetics underpinning these observations, but unfortunately
these were not able to be conducted at this time.
Biochemistry
Admission blood samples from the same 33 patients were
screened for biochemical abnormalities. No major abnormalities
were noted in terms of electrolytes, blood glucose, renal function
and liver function tests. Minor abnormalities included median
venous bicarbonate of 14 mmol/L (IQR 10–15 mmol/L) and the
median anion gap was raised at 20 mmol/L (IQR 18–26 mmol/
L). We were not able to perform arterial blood gases which might
Figure 2. Admission imidacloprid plasma concentrations
(n=33). Compared to other cases of imidacloprid poisoning where
the plasma concentration was quantified (12.5 and 2.05 ng/L post-
mortem [16]), our patients survived despite relatively high concentra-
tions.
doi:10.1371/journal.pone.0005127.g002
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Median creatine kinase (CK) was measured at 115 IU/L (IQR
75–124), which is within the commonly quoted reference range
and troponin-I was not elevated.
Discussion
This is the only prospective human case series reporting
outcomes from acute self-poisoning with the neonicotinoid
insecticide imidacloprid. We demonstrated that imidacloprid
self-poisoning resulted in mostly minor toxicity with a case-fatality
of 0%. This is favourable compared to outcomes with other
insecticides, in particular the widely used organophosphorus
compounds which commonly have a case fatality between 5 and
30% [23,24]. The most severely poisoned patients were both
administered antidotes used for the treatment of organophospho-
rus pesticides (a common cause of poisonings in the region) and
this may have increased the apparent toxicity. Many patients may
have had a moderate metabolic acidosis on admission; however,
simple supportive care was sufficient to ensure a good outcome for
all patients in this series.
Tachycardia and hypertension have usually been reported in
previous cases, and recurrent ventricular fibrillation was the
reported cause of death in a 69 year-old woman with coronary
artery disease [18]. Only 2 patients in our case series developed
any cardiovascular toxicity which was predominantly hypotension
and biomarkers of cardiac toxicity were not elevated. While
electrocardiographic monitoring was not conducted in these
patients, blood pressure improved with intravenous fluids.
Therefore serious arrhythmias were unlikely to have caused the
hypotension.
Biochemical abnormalities and rhabdomyolysis have been
reported as potentially serious complications that might lead to
mortality [15,21]. Most of the patients in our series had normal
CK and biochemistry with the exception of low venous
bicarbonate. The cause of this is not clear given the other
biochemical results, although diarrhoea may be contributory. It
may also be due to acidic metabolites of imidacloprid such as 6-
chloronicotinic acid and other metabolites [6]; however, metabolic
pathways of imidacloprid have not been extensively studied in
humans. Direct mitochondrial toxicity from a component of the
formulation (as observed with some other pesticides) may cause
anaerobic metabolism and produce a lactic acidosis which may
cause a moderate decrease in bicarbonate.
In animals, imidacloprid penetrates the blood-brain barrier to
only a very limited extent [7]. While a decreased level of
consciousness was uncommon in our study, prolonged sedation
and respiratory depression was noted in two patients which may
have been due to co-ingestion of ethanol. Transient respiratory
impairment appeared to contribute to deaths reported in patients
with severe poisoning where co-ingestion of ethanol was not
reported [20,21].
There are no specific antidotes for neonicotinoid poisoning in
mammals [7,25]. On the basis of our experience, symptomatic and
supportive care is all that is required for the management of
patients with acute imidacloprid poisoning. Treatment with
oximes such as pralidoxime is expected to be either ineffective
or contraindicated. Oximes in the absence of organophosphorus
pesticides have a weak inhibitory effect on acetylcholinesterase
activity and therefore might increase nicotinic effects (tachycardia,
hypertension, muscle weakness). It is notable that our two most
seriously poisoned cases received treatment with pralidoxime.
The concentration-time profile shown in Figure 3 suggests that
there is rapid absorption, with high concentrations being noted on
admission. In rats, imidacloprid is rapidly and almost completely
absorbed (.92%) from the gastrointestinal tract. The peak plasma
concentration is observed within approximately 2.5 hours and is
followed by a rapid disposition phase. However, in our patients the
concentrations generally remained elevated for up to 10–15 hours
post-ingestion, which might suggest saturation of one or more
kinetic (absorption or elimination) pathways in humans at high
doses. A possible factor influencing the observed kinetic profile is
the administration of atropine (commonly given routinely to
insecticide poisonings in Sri Lanka) which is known to prolong the
absorption phase of xenobiotics [26].
Of the patients who provided serial samples, the final blood
sample was generally obtained from patients around the time of
discharge, when they appeared to be in good health. It is noted in
figure 3 that for many of these patients the imidacloprid
concentration remained elevated. Therefore, plasma concentra-
tions do not appear to be useful for guiding clinical management,
which may reflect the contribution of metabolites or co-
formulants. In rats, the metabolism of imidacloprid is rapid and
extensive where only 10–16% of a dose is excreted unchanged [6].
Metabolites may contribute to human toxicity as they do in insects,
in particular the olefin metabolite which retains insecticidal
activity and nAChR activity [7]. Potentially, individual variation
in cytochrome P450 isoenzymes involved in oxidative imidaclo-
prid metabolism may contribute to variable toxicity [7,27].
Admire SL 200H (200 g/L), the most popular imidacloprid-
containing product in Sri Lanka, contains dimethylsulfoxide and
N-methylpyrolidone as solvents which are irritants and may
induce gastrointestinal toxicity.
Four deaths have been reported in the literature, and the post-
mortem blood concentrations in two cases were 12.5 and 2.05 ng/
L [16], which surprisingly is not substantially greater than the
median plasma concentration in our study (9.86 ng/L). However,
ante-mortem plasma concentrations were not reported in these
two fatalities and a direct comparison of the concentrations may
be misleading. There are no data on the blood/plasma
concentration ratio or post-mortem redistribution.
This study demonstrates that an acute ingestion of 20% SL
formulations of imidacloprid, even following large ingestions in
patients with self-poisoning, is relatively safe. Therefore, it may be
advantageous to promote the use of imidacloprid or similar
Figure 3. The toxicokinetics of imidacloprid in patients with
self-poisoning (n=8 patients). The concentration was high on
admission and remained elevated in the majority of patients suggesting
either prolonged absorption and/or elimination.
doi:10.1371/journal.pone.0005127.g003
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However, before this occur the relative risks and benefits of this
insecticide (which has been debated)[28,29,30] must be compared
to those of existing pesticides. This will require careful consider-
ation by independent regulatory authorities.
Imidacloprid pesticides appear to be of low toxicity to humans
causing only mild symptoms such as vomiting, abdominal pain,
headache and diarrhoea in the majority of cases. Large ingestions
may lead to sedation and respiratory arrest. Patients with a low
GCS should be closely monitored for onset of respiratory
compromise but most patients only need symptomatic and
supportive care. More research is required to show if the
replacement in agriculture of older anti-cholinesterase pesticides
with newer pesticides with much lower in-hospital case-fatality will
lead to an overall reduction in deaths from self-poisoning.
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